At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Parallel-Design, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Glargine in Adults With Type 2 Diabetes on Multiple Daily Injections
In Brief
A Phase 3 clinical trial evaluating Insulin Efsitora Alfa, Insulin Lispro (U100), and 1 other intervention for Type 2 Diabetes and Type 2 Diabetes Treated With Insulin. Completed, enrolled 730 participants across 81 sites in 8 countries.
Detailed Summary
The reason for this study is to evaluate if the once-weekly study drug insulin efsitora alfa (LY3209590) is safe and effective compared with daily insulin glargine in participants with Type 2 diabetes (T2D) that have already been treated with basal insulin and at least 2 injections per day of prandial insulin. The study consists of a 3-week screening/lead-in period, a 26-week treatment period and a 5-week safety follow-up period. The study will last up to 34 weeks.
Study Details
Timeline
Interventions
Administered SC
Administered SC
Administered SC